Publication: Development of new HLA-B*3505 genotyping method using invader assay
1
Issued Date
2010-10-01
Resource Type
ISSN
17446880
17446872
17446872
Other identifier(s)
2-s2.0-77957222123
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Pharmacogenetics and Genomics. Vol.20, No.10 (2010), 630-633
Suggested Citation
Naoya Hosono, Soranun Chantarangsu, Kazuma Kiyotani, Sadaaki Takata, Yumiko Tsuchiya, Surakameth Mahasirimongkol, Wasun Chantratita, Taisei Mushiroda, Yusuke Nakamura, Michiaki Kubo Development of new HLA-B*3505 genotyping method using invader assay. Pharmacogenetics and Genomics. Vol.20, No.10 (2010), 630-633. doi:10.1097/FPC.0b013e32833ddc0a Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/28635
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Development of new HLA-B*3505 genotyping method using invader assay
Abstract
Several pharmacogenetic studies have revealed strong associations between specific human leukocyte antigen (HLA) alleles and the susceptibility to drug hypersensitivity. Recently, we reported HLA-B*3505 as a strong genetic biomarker for the nevirapine-induced skin rash in Thai population. Here, we developed a new HLA-B*3505 genotyping method by a combination of the Universal Invader assay and sequence-specific primer PCR. From the sequence alignment of 68 HLA-B alleles in the Thai population, we selected the two most discriminative SNPs (rs1140412 and rs4997052) as target SNP sites. When we carried out the assay using 324 Thai individuals, fluorescence intensities of HLA-B*3505-positive and HLA-B*3505-negative samples were apparently discriminated at the endpoint of the reaction. Our results were 100% concordant with those obtained by a sequence-based typing method. As our assay is simple and rapid, we believe our method will be a useful tool for pharmacogenetic testing of the nevirapine-induced skin rash. © 2010 Wolters Kluwer Health | Lippincott Williams & Wilkins.